WallStSmart

Guardian Pharmacy Services, Inc. (GRDN)vsJohnson & Johnson (JNJ)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Johnson & Johnson generates 6552% more annual revenue ($96.36B vs $1.45B). JNJ leads profitability with a 21.8% profit margin vs 3.4%. JNJ trades at a lower P/E of 26.3x. JNJ earns a higher WallStSmart Score of 59/100 (C).

GRDN

Hold

46

out of 100

Grade: D+

Growth: 6.7Profit: 7.0Value: 6.3Quality: 5.8
Piotroski: 3/9Altman Z: 6.06

JNJ

Buy

59

out of 100

Grade: C

Growth: 4.7Profit: 9.0Value: 3.3Quality: 6.0
Piotroski: 4/9Altman Z: 2.64
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

GRDNUndervalued (+79.3%)

Margin of Safety

+79.3%

Fair Value

$166.71

Current Price

$37.10

$129.61 discount

UndervaluedFair: $166.71Overvalued
JNJSignificantly Overvalued (-43.5%)

Margin of Safety

-43.5%

Fair Value

$160.13

Current Price

$229.85

$69.72 premium

UndervaluedFair: $160.13Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

GRDN3 strengths · Avg: 9.0/10
Altman Z-ScoreHealth
6.0610/10

Safe zone — low bankruptcy risk

Return on EquityProfitability
26.6%9/10

Every $100 of equity generates 27 in profit

Revenue GrowthGrowth
17.4%8/10

17.4% revenue growth

JNJ5 strengths · Avg: 8.8/10
Market CapQuality
$547.28B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
26.4%9/10

Every $100 of equity generates 26 in profit

Profit MarginProfitability
21.8%9/10

Keeps 22 of every $100 in revenue as profit

Operating MarginProfitability
27.4%8/10

Strong operational efficiency at 27.4%

Free Cash FlowQuality
$1.47B8/10

Generating 1.5B in free cash flow

Areas to Watch

GRDN4 concerns · Avg: 3.5/10
Price/BookValuation
11.4x4/10

Trading at 11.4x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
3.4%3/10

3.4% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

JNJ3 concerns · Avg: 2.7/10
P/E RatioValuation
26.3x4/10

Moderate valuation

PEG RatioValuation
2.962/10

Expensive relative to growth rate

EPS GrowthGrowth
-52.9%2/10

Earnings declined 52.9%

Comparative Analysis Report

WallStSmart Research

Bull Case : GRDN

The strongest argument for GRDN centers on Altman Z-Score, Return on Equity, Revenue Growth. Revenue growth of 17.4% demonstrates continued momentum.

Bull Case : JNJ

The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.

Bear Case : GRDN

The primary concerns for GRDN are Price/Book, EPS Growth, Profit Margin. A P/E of 48.2x leaves little room for execution misses. Thin 3.4% margins leave little buffer for downturns.

Bear Case : JNJ

The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.

Key Dynamics to Monitor

GRDN profiles as a growth stock while JNJ is a mature play — different risk/reward profiles.

GRDN is growing revenue faster at 17.4% — sustainability is the question.

JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.

Monitor MEDICAL CARE FACILITIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

JNJ scores higher overall (59/100 vs 46/100), backed by strong 21.8% margins. GRDN offers better value entry with a 79.3% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Guardian Pharmacy Services, Inc.

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Guardian Pharmacy Services, Inc. is a premier provider of specialized pharmacy solutions tailor-made for the long-term care sector, encompassing assisted living and skilled nursing facilities. The company distinguishes itself through a commitment to personalized medication management, rigorous standards of quality and compliance, and exceptional customer service. By leveraging state-of-the-art technology and extensive pharmaceutical expertise, Guardian enhances patient outcomes while optimizing workflows for healthcare partners. With a robust operational footprint across multiple states, the company is strategically positioned to meet the increasing demand for customized pharmacy services in a dynamic healthcare landscape.

Johnson & Johnson

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.

Visit Website →

Want to dig deeper into these stocks?